|
| Tuesday, July 23, 2024 |
|
|
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases |
| Sirnaomics Ltd. (HKG: 2257) a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced that it has completed IND-enabling studies for STP125G, an siRNA therapeutics targeting Apolipoprotein C3 (ApoC3), based on its proprietary GalAheadTM mxRNA technology. more info >> |
|
| Tuesday, December 20, 2022 |
|
|
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors |
| Sirnaomics Ltd. (Stock Code: 2257.HK) (the "Company", together with its subsidiaries, "Sirnaomics" or the "Group"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results from a Phase I clinical trial evaluating the safety more info >> |
|
| Wednesday, December 14, 2022 |
|
|
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results of part-one of an ongoing Phase IIb clinical trial of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC). more info >> |
|
|
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022 |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Executive Director Dr. Xiaochang Dai will deliver a keynote speech at BIOHK2022, the first major biotech conference to be held in Hong Kong since the outbreak of the COVID-19 pandemic. more info >> |
|
| Tuesday, November 8, 2022 |
|
|
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the Company has dosed the first patient in a Phase I clinical study of STP705, a siRNA (small interfering RNA) drug candidate, for the study of fat reduction in adults undergoing abdominoplasty. more info >> |
|
| Wednesday, October 19, 2022 |
|
|
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on GalAhead(TM), a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston more info >> |
|
| Tuesday, September 20, 2022 |
|
|
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics more info >> |
|
| Tuesday, September 6, 2022 |
|
|
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today more info >> |
|
| Monday, August 29, 2022 |
|
|
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the cohort receiving the 180ug dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response (CR) more info >> |
|
| Friday, August 26, 2022 |
|
|
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead(TM) RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. more info >> |
|
|
|
